Kadmon reports Phase II data for IPF candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported top-line data from the U.S. Phase II KD025-207 trial of KD025 to treat idiopathic pulmonary fibrosis (IPF) in patients previously treated with or offered Esbriet pirfenidone or Ofev nintedanib.

The company

Read the full 356 word article

User Sign In